Aquestive Therapeutics Reports Third Quarter 2023 Financial

Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data...

Related Keywords

Daniel Barber ,Stephanie Carrington ,Indivior Suboxone ,Aquestive Therapeutics Inc ,Nasdaq ,Development Expense ,Linkedin ,Drug Administration ,Exchange Commission ,Senior Secured Notes Of The Company ,Sublingual Film ,Chief Executive Officer ,New Drug Application ,Buccal Film ,Rectal Gel ,Riluzole Oral Film ,Lennox Gastaut Syndrome ,Attention Deficit Hyperactivity Disorder ,Senior Secured Notes ,Note Holders ,Conference Call ,Private Securities Litigation Reform Act ,Quarterly Reports ,Current Reports ,Aquestive Therapeutics ,Consolidated Statements ,Comprehensive Income ,Nasdaq Aqst ,Nc ,